Personal history of cancer as a risk factor for second primary lung cancer: Implications for lung cancer screening.

"data s1: acknowledgments this work was supported by the national cancer institute grant r37ca271187 (pi: toumazis) to i t; the generous philanthropic contributions to the university of texas md anderson cancer center lung moon shot to j h i t and j z; the generous philanthropic contributions from andrea mugnaini and edward l c smith to s n; in part by a cancer prevention fellowship supported by the national cancer institute grant r25e (ca056452 shine chang ph d principal investigator) to p r; and in part by the md anderson cancer center support grant from the national cancer institute of the national institutes of health (nci/nih p30 ca016672)."

"CONFLICT OF INTEREST STATEMENT All authors have no conflicts of interest except the following: Sara Nofal reports support for the submitted work from the generous philanthropic contributions to The University of Texas MD Anderson Cancer Center Lung Moon Shot, the generous philanthropic contributions from Andrea Mugnaini and Edward L. C. Smith, and the National Cancer Institute grant R37CA271187 (PI: Toumazis). Paul. J. Resong reports support for the submitted work from a cancer prevention fellowship by the National Cancer Institute grant R25E (CA056452, Shine Chang, Ph.D., Principal Investigator) (in part). Iakovos Toumazis reports support for the submitted work from the National Cancer Institute grant R37CA271187 (PI: Toumazis), R25ECA056452 (in kind), and the generous philanthropic contributions to The University of Texas MD Anderson Cancer Center Lung Moon Shot (in part). Edwin Ostrin reports grant/contract by the Early Detection Research Network Clinical Validation Center (NCI) and payment/honoraria for Astra Zeneca (April 2021) outside the submitted work. Jianjun Zhang reports grants from Merck, grants and personal fees from Johnson and Johnson and Novartis, personal fees from Bristol Myers Squibb, AstraZeneca, GenePlus, Innovent and Hengrui outside the submitted work as well as support for the submitted work from the National Cancer Institute of the National Institute of Health Research Project Grant (R01CA234629), the AACR‐Johnson & Johnson Lung Cancer Innovation Science Grant (18‐90‐52‐ZHAN), and the MD Anderson Physician Scientist Program, MD Anderson Lung Cancer Moon Shot Program. Xiuning Le reports outside the submitted work grants/contracts from Eli Lilly, EMD Serono, Boehringer Ingelheim, and Regeneron; consulting fees from EMD Serono (Merck KGaA), AstraZeneca, Spectrum Pharmaceutics, Novartis, Eli Lilly, Boehringer Ingelheim, Hengrui Therapeutics AstraZeneca, Janssen, Blueprint Medicines, Sensei Biotherapeutics, Daiichi Sankyo, Regeneron, Abbvie, and ArriVent; and support for meetings/travel from Spectrum Therapeutics and EMD Serono."

"This work was supported by the National Cancer Institute grant R37CA271187 (PI: Toumazis) to I.T.; the generous philanthropic contributions to The University of Texas MD Anderson Cancer Center Lung Moon Shot to J.H., I.T., and J.Z; the generous philanthropic contributions from Andrea Mugnaini and Edward L. C. Smith to S.N.; in part by a cancer prevention fellowship supported by the National Cancer Institute grant R25E (CA056452, Shine Chang, Ph.D., Principal Investigator) to P.R.; and in part by the MD Anderson Cancer Center Support Grant from the National Cancer Institute of the National Institutes of Health (NCI/NIH P30 CA016672). The funders did not play a role in the design of the study; the collection, analysis, and interpretation of the data; the writing of the manuscript; and the decision to submit the manuscript for publication. All authors have no conflicts of interest except the following: Sara Nofal reports support for the submitted work from the generous philanthropic contributions to The University of Texas MD Anderson Cancer Center Lung Moon Shot, the generous philanthropic contributions from Andrea Mugnaini and Edward L. C. Smith, and the National Cancer Institute grant R37CA271187 (PI: Toumazis). Paul. J. Resong reports support for the submitted work from a cancer prevention fellowship by the National Cancer Institute grant R25E (CA056452, Shine Chang, Ph.D., Principal Investigator) (in part). Iakovos Toumazis reports support for the submitted work from the National Cancer Institute grant R37CA271187 (PI: Toumazis), R25ECA056452 (in kind), and the generous philanthropic contributions to The University of Texas MD Anderson Cancer Center Lung Moon Shot (in part). Edwin Ostrin reports grant/contract by the Early Detection Research Network Clinical Validation Center (NCI) and payment/honoraria for Astra Zeneca (April 2021) outside the submitted work. Jianjun Zhang reports grants from Merck, grants and personal fees from Johnson and Johnson and Novartis, personal fees from Bristol Myers Squibb, AstraZeneca, GenePlus, Innovent and Hengrui outside the submitted work as well as support for the submitted work from the National Cancer Institute of the National Institute of Health Research Project Grant (R01CA234629), the AACR‐Johnson & Johnson Lung Cancer Innovation Science Grant (18‐90‐52‐ZHAN), and the MD Anderson Physician Scientist Program, MD Anderson Lung Cancer Moon Shot Program. Xiuning Le reports outside the submitted work grants/contracts from Eli Lilly, EMD Serono, Boehringer Ingelheim, and Regeneron; consulting fees from EMD Serono (Merck KGaA), AstraZeneca, Spectrum Pharmaceutics, Novartis, Eli Lilly, Boehringer Ingelheim, Hengrui Therapeutics AstraZeneca, Janssen, Blueprint Medicines, Sensei Biotherapeutics, Daiichi Sankyo, Regeneron, Abbvie, and ArriVent; and support for meetings/travel from Spectrum Therapeutics and EMD Serono."